24/7 Market News Snapshot 25 Jul 2024 – MIRA Pharmaceuticals, Inc. Common Stock (NASDAQ: MIRA)

July 25, 2024 6:16

Press Release

DENVER, Colo., 25 July, 2024 (247marketnews.com) – (NASDAQ:MIRA) are discussed in this article.
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is making headlines with its Common Stock (MIRA) witnessing an impressive surge in the pre-market trading session, soaring from $2.36 to $3.09. With a substantial trading volume of 1.2M shares and a remarkable change percentage of 26.23, investors are taking notice of MIRA’s strong growth potential, fueling excitement in the market. Analysts predict a continued uptrend for MIRA, presenting an attractive opportunity for savvy investors seeking profitable ventures.

Adding to the excitement is MIRA Pharmaceuticals’ recent announcement unveiling positive preclinical data for its innovative oral ketamine analog, Ketamir-2, a potential game-changer in the realm of neurological and neuropsychiatric disorder treatments. This groundbreaking compound exhibited selective inhibition of the NMDA receptor of glutamate, showcasing a unique pharmacological profile distinct from traditional ketamine. The preclinical studies highlighted Ketamir-2’s enhanced safety profile, with studies in rats and dogs demonstrating no toxicity at high doses, positioning it as a safe and effective candidate for human therapies.

Erez Aminov, Chairman & CEO of MIRA Pharmaceuticals, expressed optimism about Ketamir-2’s development progress, emphasizing its transformative potential in mental health treatment. Dr. Itzchak Angel, Chief Scientific Advisor, underscored the compound’s remarkable selectivity and safety attributes, setting the stage for innovative therapeutic solutions in the field.

With its sights set on an Investigational New Drug Application (IND) submission later this year, MIRA Pharmaceuticals is poised to advance Ketamir-2 into human clinical trials, offering hope to individuals grappling with treatment-resistant depression and PTSD. The company’s pioneering approach in developing novel treatments for neurologic and neuropsychiatric disorders underscores its commitment to driving impactful advancements in healthcare innovation.

For more information about MIRA Pharmaceuticals and its groundbreaking programs, visit www.mirapharmaceuticals.com. Stay tuned for further updates on MIRA Pharmaceuticals’ cutting-edge contributions to revolutionizing healthcare solutions.

Source: MIRA Pharmaceuticals, Inc.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 Market News, Inc Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.